 Skye Bioscience Inc OTCQB:SKYE said it has been advised by its contract manufacturer that it has completed the production of SBI-100 Ophthalmic Emulsion SBI-100 OE for Skyes phase one clinical trial as a treatment for glaucoma, the worlds leading cause of irreversible blindness. The final drug product will be released and available for clinical use in October, following receipt of acceptable results from quality and analytical testing, according to San Diego-based Skye Bio. 